



A31386-A - 070165.0593

PATENT

ap/1642 \$/✓

p#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 18 2002

TECH CENTER 1600/2900

Applicant : Coller et al.

Serial No. : 09/855,886 Examiner : Helms, L.

Filing Date : May 15, 2001 Group Art : 1642

Title of Invention : METHOD OF INHIBITING ANGIOGENESIS AND TUMOR GROWTH AND PREVENTING TUMOR GROWTH AND METASTASES

INFORMATION
DISCLOSURE
STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231

July 10, 2002

Date of Deposit

Lisa B. Kole, M.D., Ph.D.

Attorney Name

Signature

35,225

PTO Registration No.

July 10, 2002

Date of Signature

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants respectfully request that the citations listed herein be considered by the Examiner and made of record in the above-mentioned application. The citations listed below are also listed in the accompanying PTO



RECEIVED

JUL 18 2002

A31386-A - 070165.0593
PATENT

TECH CENTER 1600/2900

Form 1449. The Examiner's attention is particularly invited to the citations marked with an asterisk (*), which are deemed to be particularly pertinent.

- *1. *Fundamental Immunology*, Paul W.E. ed., 4th Edition, 1999. Lippincott Williams & Wilkins Publishers, p. 242.
- *2. Varner JA, Nakada MT, Jordan RE, Collier BS (1999). Inhibition of angiogenesis and tumor growth by murine 7E3, the parent antibody of c7E3 Fab (abciximab; ReoPro™). *Angiogenesis* 3:53-60.
- *3. Arap W, Pasqualini R, Ruoslahti E (1998). Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. *Science* 279:377-380.
- 4. Bombeli T, Schwartz BR, Harlan JM (1998). Adhesion of activated platelets to endothelial cells: evidence for a GPIIb/IIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), $\alpha_v\beta_3$ integrin, and GPIb α . *J. Exp. Med.* 187(3):329-339.
- *5. Tam SH, Sassoli PM, Jordan RE, Nakada MT (1998). Abciximab (ReoPro, Chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and $\alpha_v\beta_3$ integrins. *Circulation* 98(11):1085-1091.
- 6. U.S. Patent No. 5,753,230 by Brooks *et al.*, issued May 19, 1998 and entitled "Methods and compositions useful for inhibition of angiogenesis."

- *7. U.S. Patent No. 5,780,426 by Palladino *et al.*, issued July 14, 1998 and entitled "Fivemer cyclic peptide inhibitors of diseases involving $\alpha_v\beta_3$ integrins."
- *8. Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD (1998). Stepwise in vitro affinity maturation of Vitaxin, an $\alpha_v\beta_3$ -specific humanized mAb. Proc. Natl. Acad. Sci. USA 95(11):6037-6042.
- 9. Collier BS (1997). Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. Perspectives Series: Cell Adhesion in Vascular Biology. J. Clin. Invest. (Suppl.) 100 (11):S57-S60.
- *10. Nakada MT, Jordan RE, Knight DM (1997). Abciximab (ReoPro, chimeric 7E3 Fab) cross-specificity with $\alpha_v\beta_3$ integrin receptors: a potential mechanism for the prevention of restenosis " J. Amer. Coll. Cardiol. 29(2):243A (abstract).
- *11. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57(20):4593-4599.
- *12. Taylor FB, Collier BS, Chang AC, Peer G, Jordan R, Engellener W, Esmon CT (1997). 7E3 F(ab')₂, Monoclonal antibody to the platelet GPIIb/IIIa receptor, protects against microangiopathic hemolytic anemia and microvascular thrombotic renal failure in baboons treated with C4b binding protein and a sublethal infusion of *Escherichia coli*. Blood 89(11): 4078-4084.

- *13. Varner JA (1997). The role of vascular cell integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ in angiogenesis. In: Regulation of Angiogenesis, Goldberg and Rosen, eds., Basel: Birkheuser Verlag, Volume 79, pp. 361-390.
- *14. Varner JA, Nakada M, Jordan R, Collier B (1997). Anti-angiogenic properties of 7E3, an integrin β_3 subunit antagonist, in the SCID mouse-human skin model of human angiogenesis" Thromb. Haemost. 77 (Suppl.):158 (abstract PD-645) (Abstracts presented June 6-12, 1997 at the 15th meeting in Florence, Italy).
- 15. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
- *16. Collier BS, Anderson KM, Weisman HF (1996). The anti-GPIIb-IIIa agents: fundamental and clinical aspects. Haemostasis 26 (Suppl 4):285-293.
- *17. Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresch DA (1996). Involvement of integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA 93(18):9764-9769.
- *18. Marcinkiewicz C, Rosenthal LA, Mosser DM, Kunicki TJ, Niewiarowski S (1996). Immunological characterization of eristostatin and echistatin binding sites on $\alpha_{IIb}\beta_3$ and $\alpha_v\beta_3$ integrins. Biochem. J. 317:817-825.

- *19. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Collier BS (1996). Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. *J. Clin. Invest.* 98:863-874.
- *20. Varner JA, Cheresh DA (1996). Integrins and cancer. *Curr. Opin. Cell. Biol.* 8(5):724-730.
- *21. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995). Definition of two angiogenic pathways by distinct α_v integrins. *Science* 270:1500-1502.
- *22. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995). Antiintegrin $\alpha_v\beta_3$ blocks human breast cancer growth and angiogenesis in human skin. *J. Clin. Invest.* 96:1815-1822.
- 23. U.S. Patent No. 5,440,020 by Collier, issued August 8, 1995 and entitled "Platelet function inhibiting monoclonal antibody fragment."
- 24. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. *Hum. Pathol.* 26(1):86-91.
- 25. Hatva E, Kaipainen A, Mentula P, Jaaskelainen J, Paetau A, Haltia M, Alitalo K (1995). Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. *Amer. J. Pathol.* 146 (2):368-378.

26. International Patent Application PCT/US94/12779 by Coller *et al.*, published as WO95/12412 on 11 May 1995 and entitled "Platelet-specific chimeric immunoglobulin and methods of use therefor."
27. U.S. Patent No. 5,387,413 by Coller, issued Feb. 7, 1995 and entitled "Method of inhibiting thrombus formation by the 7E3 monoclonal antibody."
- *28. Brooks PC, Clark RA, Cheresh DA (1994). Requirement of vascular integrin $\alpha_v\beta_3$ for angiogenesis. *Science* 264:569-571.
- *29. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994). Integrin $\alpha_v\beta_3$ antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. *Cell* 79:1157-1164.
30. Coller BS, Seligsohn U, Peretz H, Newman PJ (1994). Glanzmann thrombasthenia: new insights from an historical perspective. *Semin Hematol* 31(4):301-311.
31. DeLisser HM, Newman PJ, Albelda SM (1994). Molecular and functional aspects of PECAM-1/CD31. *Immunol. Today* 15(10):490-495.
32. Leek RD, Harris AL, Lewis CE (1994). Cytokine networks in solid human tumors: regulation of angiogenesis. *J. Leukoc. Biol.* 56:423-435.
33. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases. *Cell* 79:315-328.

- *34. Seaver S. Genetic Engineering News, August 10, 1994, Volume 14, pp. 10 and 21
- *35. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, *et al.* (1994). Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. *Lancet* 1343(8902):881-886.
- 36. Vartanian RK, Weidner N (1994). Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. *Am. J. Pathol.* 144(6):1188-1194.
- 37. Weinstat-Saslow D, Steeg PS (1994). Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. *FASEB J* 8:401-407.
- 38. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, Senger DR (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. *Amer. J. Path.* 143:1255-1262.
- 39. Felding-Habermann B, Mueller BM, Romerdahl CA, Cheresch DA (1992). Involvement of integrin alpha V gene expression in human melanoma tumorigenicity. *J. Clin. Invest.* 89(6):2018-2022.
- 40. Folkman J (1992). The role of angiogenesis in tumor growth. *Sem. Cancer Biol.* 3:65-71.

41. Plate KH, Breier G, Weich HA, Risau W (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas *in vivo*. Nature 359:845-848.
- *42. Wayner EA, Orlando RA, Cheresch DA (1991). Integrins $\alpha_v\beta_5$ contribute to cell attachment to vitronectin but differentially distribute on the cell surface. J. Cell Biol. 113:919-929.
43. Liotta LA, Steeg PS, Stetler-Stevenson WG (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336.
44. Weidner N, Semple JP, Welch WR, Folkman J (1991). Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl. J. Med. 324:1-8.
- *45. Coller BS, Cheresch DA, Asch E, Seligsohn U (1991). Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood 77:75-83.
46. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iulucci J, Knight D, Ghayeb J, Smith C, Weisman HF, Berger H (1991). Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann. NY Acad. Sci. 614:193-213.
- *47. Bowie JU, Reidhaar-Olson JF, Lim WA, Sauer RT (1990). Deciphering the message in protein sequences: tolerance to amino acid substitutions. Science 247(4948):1306-1310.

48. Blood CH, Zetter BR (1990). Tumor interactions with the vasculature: angiogenesis and tumor metastasis. *Biochim. Biophys. Acta* 1032:89-118.
- *49. Burgess WH, Shaheen AM, Ravera M, Jaye M, Donohue PJ, Winkles JA (1990). Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. *J. Cell Biol.* 111(5 Pt 1):2129-2138.
- *50. Lazar E, Vicenzi E, Van Obberghen-Schilling E, Wolff B, Dalton S, Watanabe S, Sporn MB (1989). Transforming growth factor alpha: an aromatic side chain at position 38 is essential for biological activity. *Mol. Cell Biol.* 9(2):860-864.
- *51. Tao MH, Morrison SL (1989). Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. *J. Immunol.* 143(8):2595-2601.
- *52. Karparkin S, Pearlstein E, Ambrogio C, Collier BS (1988). Role of adhesive proteins in platelet tumor interactions in vitro and metastasis formation in vivo. *J. Clin. Invest.* 81:1012-1019.
53. Folkman J, Klagsbrun M (1987). Angiogenic factors. *Science* 235:442-447.
54. Cheresh DA (1987). Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. *Proc. Natl. Acad. Sci. U.S.A.* 84:6471-6475.

- *55. Collier BS (1986). Activation affects access to the platelet receptor for adhesive glycoproteins. *J. Cell. Biol.* 103:451-456.
- *56. Collier BS (1985). A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. *J. Clin. Invest.* 76:101-108.
- 57. U.S. Patent No. 4,474,893 by Reading, issued Oct. 2, 1984 and entitled "Recombinant monoclonal antibodies."
- 58. Collier BS, Peerschke EI, Scudder LE, Sullivan CA (1983). A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. *J. Clin. Invest.* 72:325-338.
- 59. *Harrison's Principles of Internal Medicine*. Petersdorf *et al.*, eds. 10th Edition, 1983. McGraw-Hill Professional Publishing. pp. 1868-1869.
- 60. Levy R, Dilley J, Lampson LA (1978). Human normal and leukemia cell surface antigens. Mouse monoclonal antibodies as probes. *Curr. Top. Microbiol. Immunol.* 81:164-169.
- *61. Sevier ED, David GS, Martinis J, Desmond WJ, Bartholomew RM, Wang R (1981). Monoclonal antibodies in clinical immunology. *Clin. Chem.* 27(11):1797-1806.



RECEIVED

JUL 18 2002

TECH CENTER 1600/2900

A31386-A - 070165.0593
PATENT

Identification of the above-listed citations is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as "prior art" against the subject application, nor shall the filing of this Information Disclosure Statement be construed as a representation that no material references other than those listed exist or that a search has been conducted.

Pursuant to 37 C.F.R. § 1.98(c), Applicants enclose a fee of \$180.00 as specified by 37 C.F.R. § 1.17(p). Applicants believe no other fees are required for submission of this Information Disclosure Statement. If, however, any fees are required, please charge our Deposit Account No. 02-4377. Two copies of this paper are enclosed.

Respectfully submitted,

BAKER BOTTS L.L.P.

Lisa B. Kole, M.D., Ph.D.

Patent Office Reg. No. 35,225

Attorney for Applicants

(212) 408-2628

Enclosures